Amir Ameri

Amir Ameri is a board-certified medical oncologist and currently serves as the Medical Director of Immuno-Oncology at GSK. They completed a Doctor of Medicine degree at Harvard Medical School in 2019. Prior to their current role, Amir held fellowships and research positions at prominent institutions including the National Cancer Institute, where they studied the role of EGR1 in prostate cancer bone metastasis, and Johns Hopkins Hospital, where they developed a neutrophil-driven immunotherapy against solid tumors. Additionally, Amir contributed to cancer research at Massachusetts General Hospital and the Harvard Stem Cell Institute, utilizing techniques such as CRISPR/Cas9 gene editing.